Table 4.

Conjugating enzyme‐miRNA pair correlations consistent with miRNA modulation of conjugating enzyme gene expression in response to rifampin treatment

miRNA	Gene 2	Correlation coefficienta	P‐value
Positive correlation
hsa‐miR‐638	GSTT1	.99	.0004
hsa‐miR‐766	GSTT1	.96	.003
hsa‐miR‐92a	UGT1A9	.93	.007
hsa‐miR‐335	GSTCD	.93	.007
hsa‐miR‐342‐3p	GSTA4	.93	.007
hsa‐miR‐92a	UGT2B11	.89	.012
hsa‐miR‐92a	UGT2B7	.89	.012
hsa‐miR‐30dc	GSTM4b	.86	.024
hsa‐miR‐660	GSTA4	.86	.024
hsa‐miR‐320	UGT3A1b	.86	.024
hsa‐miR‐616	SULT1A1	.86	.024
hsa‐miR‐200a	GSTZ1	.86	.024
hsa‐miR‐200a	GSTO1	.86	.024
hsa‐miR‐21	GSTA4	.86	.024
hsa‐miR‐886‐3p	GSTM2P1	.82	.034
hsa‐miR‐92a	TPMTb	.82	.034
hsa‐miR‐320	SULT1A1	.82	.034
HSA‐MIR‐1180	NAT15	.82	.034
hsa‐miR‐361	NAT1	.79	.048
hsa‐miR‐92a	GSTCD	.79	.048
hsa‐miR‐30dc	GSTM2	.79	.048
hsa‐miR‐660	GSTT1	.79	.048
hsa‐miR‐21	GSTT1	.79	.048
Negative correlation
hsa‐miR‐766	UGT1A3	−.96	.003
hsa‐miR‐148bc	GSTO1	−.96	.003
hsa‐miR‐200bc	SULT1A1	−.9	.006
hsa‐miR‐766	UGT2B4b	−.93	.007
hsa‐miR‐18a	UGT2B17	−.89	.012
hsa‐miR‐200bc	NAT2	−.85	.016
hsa‐miR‐107	NAT1	−.86	.024
hsa‐miR‐660	SULT1A2	−.82	.034
hsa‐miR‐638	GSTA1	−.82	.034
hsa‐miR‐638	UGT2B15	−.82	.034
hsa‐miR‐25	GSTZ1	−.82	.034
hsa‐miR‐18a	UGT2B15	−.82	.034
hsa‐miR‐23ac	UGT2B10b	−.82	.034
hsa‐miR‐744	UGT2A3	−.82	.034
hsa‐miR‐766	GSTA1	−.79	.048
hsa‐miR‐766	UGT2B15	−.79	.048
hsa‐miR‐218	GSTZ1	−.79	.048
hsa‐miR‐31	GSTO1	−.79	.048
hsa‐miR‐200bc	SULT1A2	−.76	.049

^aSpearman correlation as assumption of normal distribution could not be made. Only significant correlations reported (P < .05 by Spearman correlation). Only those genes and miRNAs significantly altered by rifampin treatment (up‐ or down‐regulated >1.25‐fold and P < .05) were included in the correlation analyses.

^bDenotes genes predicted via TargetScan to be targets of the correlated miRNA.

^cCorrespond to the nonpredominantly expressed miRNA sequence. TPMT, thiopurine S‐methyltransferase.